Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO GI 2026 View overview page

The changing treatment landscape in hepatocellular carcinoma 0:46
The changing treatment landscape in hepatocellular carcinoma
Michel Ducreux • 2 Jul 2026
Emerging cellular therapies in gastrointestinal cancers 1:41
Emerging cellular therapies in gastrointestinal cancers
Benjamin Schlechter • 2 Jul 2026
BATTMAN trial: botensilimab and balstilimab in MSS mCRC 1:14
BATTMAN trial: botensilimab and balstilimab in MSS mCRC
Benjamin Schlechter • 2 Jul 2026
Can ITE-based machine learning be used to guide treatment decisions in rBTC? 0:40
Can ITE-based machine learning be used to guide treatment decisions in rBTC?
Erman Akkus • 2 Jul 2026
Further validation of a machine learning model to guide treatment decisions for rBTC 0:47
Further validation of a machine learning model to guide treatment decisions for rBTC
Erman Akkus • 2 Jul 2026
Using ITE modeling to tailor adjuvant concurrent chemoradiotherapy or radiotherapy in BTC 1:28
Using ITE modeling to tailor adjuvant concurrent chemoradiotherapy or radiotherapy in BTC
Erman Akkus • 2 Jul 2026
Surgical resection in locally advanced pancreatic cancer 1:42
Surgical resection in locally advanced pancreatic cancer
Michele Milella • 6 Jul 2026
How does P-32 microparticle brachytherapy compare with other locoregional techniques in uLAPC? 3:43
How does P-32 microparticle brachytherapy compare with other locoregional techniques in uLAPC?
Michele Milella • 6 Jul 2026
TRIPP-FFX: targeted intratumoral P-32 microparticles with FOLFIRINOX in uLAPC 7:07
TRIPP-FFX: targeted intratumoral P-32 microparticles with FOLFIRINOX in uLAPC
Michele Milella • 6 Jul 2026
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR 1:19
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
Dirk Arnold • 10 Jul 2026
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC 1:38
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
Dirk Arnold • 10 Jul 2026
ATOMIC: does immunotherapy need chemotherapy to be beneficial in MSI-H/dMMR colon cancer? 2:48
ATOMIC: does immunotherapy need chemotherapy to be beneficial in MSI-H/dMMR colon cancer?
Dirk Arnold • 10 Jul 2026
Management of stage III colon cancer in 2026 3:50
Management of stage III colon cancer in 2026
Dirk Arnold • 10 Jul 2026
Recent developments in embolization-eligible unresectable HCC 0:49
Recent developments in embolization-eligible unresectable HCC
Stephen Lam Chan • 2 Jul 2026
Evolving treatment concepts in liver cancer in 2026 1:23
Evolving treatment concepts in liver cancer in 2026
Stephen Lam Chan • 2 Jul 2026
Can ctDNA guide cetuximab sequencing and re-challenge strategies in MSS mCRC? 0:44
Can ctDNA guide cetuximab sequencing and re-challenge strategies in MSS mCRC?
Giulia Martini • 2 Jul 2026
The content of VJOncology is intended for healthcare professionals